Loading...
XNAS
BCDA
Market cap15mUSD
Oct 07, Last price  
1.09USD
1D
2.83%
1Q
22.14%
Jan 2017
-99.25%
Name

BioCardia Inc

Chart & performance

D1W1MN
XNAS:BCDA chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
58.12%
Rev. gr., 5y
-39.41%
Revenues
0
-100.00%
0643,0001,268,0001,869,000012,00062,000268,000427,000517,000576,000479,000625,000710,000145,0001,015,0001,352,000477,00058,0000
Net income
-8m
L+3.55%
-75,444-287,000-5,800,000-5,078,000-11,509,0009,662,000305,00019,000234,000322,000-10,310,000-12,308,000-13,987,000-14,709,000-15,004,000-12,621,000-11,907,000-11,571,000-7,946,000-8,228,000
CFO
-7m
L-7.35%
-47,123-47,123-2,696,000-4,783,000-4,277,000-3,087,000-310,00027,000214,000331,000-5,522,000-8,671,000-11,069,000-9,445,000-12,357,000-10,366,000-10,561,000-9,974,000-8,026,000-7,436,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.

Key people

Peter Altman
President, Chief Executive Officer, Director · since 2016
David McClung
Chief Financial Officer · since 2019
Phil Pesta
Vice President - Operations · since 2011
Henricus Duckers
Chief Medical Officer · since 2016
Jay Moyes
Director · since 2011
Richard Pfenniger
Director · since 2016
Jim L Allen
Independent Director · since 2019
Fernando L. Fernandez
Independent Director · since 2016
Richard Krasno
Independent Director · since 2016
URL
https://www.biocardia.com/
IPO date
Nov 13, 1996
Employees
30
Domiciled in
US
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
125 Shoreway Road
Suite B
San Carlos, CA 94070
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT